Development of an in vitro assay, based on the biofilm ring test®, for rapid profiling of biofilm-growing bacteria by DI DOMENICO, Enea Gino et al.
ORIGINAL RESEARCH
published: 21 September 2016
doi: 10.3389/fmicb.2016.01429
Frontiers in Microbiology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 1429
Edited by:
Thomas Dandekar,
University of Würzburg, Germany
Reviewed by:
Giovanna Batoni,
University of Pisa, Italy
Sonia Rozental,
Federal University of Rio de Janeiro,
Brazil
*Correspondence:
Enea G. Di Domenico
enea.didomenico@ifo.gov.it
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 20 May 2016
Accepted: 29 August 2016
Published: 21 September 2016
Citation:
Di Domenico EG, Toma L, Provot C,
Ascenzioni F, Sperduti I, Prignano G,
Gallo MT, Pimpinelli F, Bordignon V,
Bernardi T and Ensoli F (2016)
Development of an in vitro Assay,
Based on the BioFilm Ring Test®, for
Rapid Profiling of Biofilm-Growing
Bacteria. Front. Microbiol. 7:1429.
doi: 10.3389/fmicb.2016.01429
Development of an in vitro Assay,
Based on the BioFilm Ring Test®, for
Rapid Profiling of Biofilm-Growing
Bacteria
Enea G. Di Domenico 1*, Luigi Toma2, Christian Provot 3, Fiorentina Ascenzioni 4,
Isabella Sperduti 5, Grazia Prignano1, Maria T. Gallo 1, Fulvia Pimpinelli 1,
Valentina Bordignon1, Thierry Bernardi 3 and Fabrizio Ensoli 1
1 Clinical Pathology and Microbiology Department, San Gallicano Institute, Istituti di Ricovero e Cura a Carattere Scientifico,
Rome, Italy, 2 Infectious Disease Consultant, San Gallicano Institute, Istituto di Ricovero e Cura a Carattere Scientifico
(IRCCS), Rome, Italy, 3 BioFilm Control, Biopole Clermont Limagne, Saint Beauzire, France, 4 Department of Biology and
Biotechnology C. Darwin, Sapienza University of Rome, Rome, Italy, 5 Biostatistics, San Gallicano Institute, Istituto di Ricovero
e Cura a Carattere Scientifico (IRCCS), Rome, Italy
Microbial biofilm represents a major virulence factor associated with chronic and
recurrent infections. Pathogenic bacteria embedded in biofilms are highly resistant
to environmental and chemical agents, including antibiotics and therefore difficult to
eradicate. Thus, reliable tests to assess biofilm formation by bacterial strains as well as the
impact of chemicals or antibiotics on biofilm formation represent desirable tools for amost
effective therapeutic management and microbiological risk control. Current methods to
evaluate biofilm formation are usually time-consuming, costly, and hardly applicable in the
clinical setting. The aim of the present study was to develop and assess a simple and
reliable in vitro procedure for the characterization of biofilm-producing bacterial strains
for future clinical applications based on the BioFilm Ring Test® (BRT) technology. The
procedure developed for clinical testing (cBRT) can provide an accurate and timely (5 h)
measurement of biofilm formation for the most common pathogenic bacteria seen in
clinical practice. The results gathered by the cBRT assay were in agreement with the
traditional crystal violet (CV) staining test, according to the κ coefficient test (κ = 0.623).
However, the cBRT assay showed higher levels of specificity (92.2%) and accuracy
(88.1%) as compared to CV. The results indicate that this procedure offers an easy, rapid
and robust assay to test microbial biofilm and a promising tool for clinical microbiology.
Keywords: biofilm, BioFilm Ring Test, crystal violet, Pseudomonas aeruginosa, Klebsiella pneumonia,
Staphylococcus aureus, Staphylococcus epidermidis, Ralstonia mannitolilytica
INTRODUCTION
Biofilm formation is a key property of microbial cells, which allows long-term survival both
in natural ecosystems and animal hosts (Høiby et al., 2010a). Bacteria growing in a biofilm
matrix are intrinsically more resistant to environmental agents and have been shown to tolerate
antibiotic concentrations 10 to 1000-fold higher than the corresponding planktonic counterpart
(Hill et al., 2005). Both Gram-positive and Gram-negative bacteria are capable of forming biofilm
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(Donlan, 2001). In fact, microbial biofilm represents a serious
problem in industry and medicine, including surgery, and
dentistry. Being responsible of high microbial adherence,
invasiveness and persistence, microbial biofilm represents a
major causative agent of chronic and recurrent infections
(Lindsay and von Holy, 2006). More than 80% of human
infectious diseases are biofilm-related, having a significant
impact on patient morbidity and healthcare costs (Römling and
Balsalobre, 2012). The formation of biofilms on implantable
medical devices causes persistent infections, which account for
more than 60% of reported nosocomial infections (Darouiche,
2004). In this setting, catheter-related infections are the
most serious and costly adverse events caused by biofilm-
producing bacteria, frequently resulting in treatment failure
and requiring the removal of the device (Costerton et al.,
2003). Typical examples of biofilm-associated diseases include
“difficult infections,” such as bone and joint infections, caused
by Staphylococcus aureus (Hackett et al., 2015; Jacqueline and
Caillon, 2014; Gbejuade et al., 2015), infective endocarditis,
mainly caused by staphylococci or streptococci, which are
associated with high mortality rates (Furuya and Lowy,
2003; Suetens et al., 2007; Otto, 2009) as well as chronic
pulmonary infections and respiratory failure caused by Klebsiella
pneumoniae (Hennequin and Robin, 2016) and Pseudomonas
aeruginosa (Høiby et al., 2010b; Ciofu et al., 2015).
Antibiotic treatment, either empirical or based on drug
resistance profiling, is often poorly effective against biofilm-
producing bacterial cells (Høiby et al., 2010a; Ciofu et al.,
2015). In fact, in addition to the production of the biofilm
extracellular matrix, biofilm-embedded cells differ from the
planktonic counterparts for other properties including a reduced
growth rate and a distinct gene expression (Beloin and Ghigo,
2005). The latter is due to the activation of complex mechanisms
of gene signaling involving 40–60% of the prokaryotic genome
(Beloin and Ghigo, 2005). These mechanisms, which allow
biofilm-producing bacteria to adapt against environmental stress
conditions, are also responsible for an increased tolerance to
antimicrobials (Beloin and Ghigo, 2005; Percival et al., 2015).
However, the antibiotic–resistance profiles are traditionally
performed in vitro on growing planktonic cells and do not take
into account the impact of biofilm production by microbial cells.
Thus, the resulting antibiotic susceptibility profile might not be
representative of the bacterial drug susceptibility/resistance in
vivo (Van Acker et al., 2014; Olsen, 2015). Laboratory assays
capable of evaluating biofilm production and the susceptibility
of biofilm-forming microorganism to antimicrobial drugs still
represent unmet needs in clinical microbiology.
An ideal diagnostic technique should be low cost, reliable
and capable of providing a timely characterization of biofilm
production by the microorganism(s) to be easily incorporated
into routine clinical laboratory testing.
A variety of quantitative methods, either direct or indirect,
have been developed (Peeters et al., 2008), either based on
colorimetric (Stepanovic et al., 2000; Joseph and Wright, 2004)
or microscopic techniques (Benoit et al., 2010; Müsken et al.,
2010). At present, the crystal violet (CV) staining is the most
widely used method for in vitro biofilm quantification, due
to its relative simplicity and sensitivity (Christensen et al.,
1985; Stepanovic et al., 2000). This method, however, presents
important limitations. In fact, it usually requires at least 24/48 h
of incubation and repeated processing steps, which lead to
large standard deviation of the readouts, making the method
neither easily feasible for standardization nor adaptable to large-
scale screening. Recently, a new technology, namely the BioFilm
Ring Test R© (BRT), has been proposed for the assessment of
bacterial biofilm. The principle is based on the immobilization
of magnetic beads by the growing biofilm matrix in vitro
(Chavant et al., 2007). The BRT method is simple and does
not require extensive handling (i.e., does not require repeated
washing and staining steps), thus allowing for the standardization
of the procedure, a necessary prerequisite to ensure clear and
reproducible readouts (Olivares et al., 2015). However, although
having a great potential, the original procedure was not capable
of providing, in a single determination, direct information about
the “dynamic” and “strength” of biofilm production by different
microorganisms. Further, it required repeated measurements, to
be performed at different time points, to estimate the formation
of microbial biofilm, posing a further, important limitation for
use in the clinical setting.
The aim of this study was to develop a simple protocol
to evaluate bacterial biofilm production based on the BRT
technology, for high throughput screening for future applications
in clinical microbiology.
The procedure relies on the measurement of biofilm
formation at an early stage. The concept is that, within a
given time period (i.e., 5 h), the fewer initial concentrations of
bacterial cells that inhibit the aggregation of the microparticles,
the stronger is their ability to produce biofilm. Conversely, if high
bacterial concentrations are not able to prevent the aggregation
of the microparticles they are considered low biofilm producers.
To test this concept, the biofilm forming ability of both Gram-
positive and Gram-negative clinical isolates was measured and
compared to that of laboratory strains with known biofilm
phenotype used as internal reference, to ensure accuracy and
reproducibility of the results. Inter-assay reproducibility was
determined by comparison with the CV assay.
MATERIALS AND METHODS
The Central Ethics Committee I.R.C.C.S. Lazio, section of the
Istituti Fisioterapici Ospitalieri in Rome, approved this study
(Prot. CE/1016/15–15 December 2015, trials registry N. 730/15).
Strains and Growth Conditions
Reference strains were from American Type Culture Collection
(ATCC): S. aureus ATCC 25923 (Sa25923) and ATCC 6538
(Sa6538); Staphylococcus epidermidis ATCC 14990 (Se14990)
and ATCC 12228 (Se12228); K. pneumoniae ATCC 700603
(Kp700603) and ATCC 13883 (Kp13883); P. aeruginosa ATCC
47085 (Pa47085), ATCC 9027 (Pa9027), and Pa14 (Pa14);
Ralstonia mannitolilytica LMG 6866 (LMG6866) and BK931
(BK931). Bacteria were cultured aerobically at 37◦C; culture
media were blood agar, chocolate agar orMcConkey agar (Oxoid,
Hampshire, UK).
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Bacterial Panel Selection
A total of 52 clinical isolates collected from patients with
nosocomial infections admitted at the IFO Hospital (Rome, It)
were assessed. Bacteria were collected from different materials
including ulcer infections, intravenous, and urinary catheter tips,
blood, urine, sputum, and nasobronchial lavage specimens. An
ulcer was classified as chronic if it existed from at least 3 months
(Dissemond, 2006). The study also included strains showing
increased resistance to commonly used antibiotics as determined
by standard Antibiotic Susceptibility Test by the VITEK2 system
(bioMérieux, Florence, Italy). In particular, P. aeruginosa isolates
resistant to three or more classes of antibiotics were considered
multidrug drug resistant organisms (MDR) (Magiorakos et al.,
2012). K. pneumoniae resistant to most beta-lactam antibiotics,
including penicillins, cephalosporins, and the monobactam
aztreonam and growing on selective chromogenic medium
chromID ESBL (bioMérieux, Florence, Italy) were classified as
extended spectrum beta-lactamase (ESBL). Phenotypic detection
of ESBL producers was further defined using disk approximation
tests (Oxoid, UK), as previously described (De Gheldre
et al., 2003; Moremi et al., 2014). K. pneumoniae resistant
to carbapenems and identified by selective chromogenic
medium chromID CARBA (bioMérieux, Florence, Italy) were
indicated as K. pneumoniae producing carbapenemases (KPC).
Methicillin-resistant Staphylococcus aureus (MRSA) were those
strains that were methicillin resistant on susceptibility testing
and producing the penicillin-binding protein (PBP) after
confirmation by PBP2′ test kit latex agglutination assay (OXOID
Ltd, Basingstoke, UK). Vancomycin-resistant enterococci (VRE)
are identified by susceptibility testing and confirmed by
selective chromogenic medium chromID VRE (bioMérieux,
Florence, Italy). Antibiotic susceptibility was defined by the
Minimum Inhibitory Concentration (MIC) interpretative criteria
recommended by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST–Clinical Breakpoint Table v
5.0). Species numbers and features of the strains tested
are reported in Table 1. Isolates were stored at −70◦C in
CRYOBANK tubes (Copan Italia spa) and grown overnight at
37◦C on specific agar plate prior to testing.
Clinical BioFilm Ring Test (cBRT) Protocol
For cBRT experiments, a fresh overnight culture of bacteria
grown on agar plate was used to inoculate, by a sterile inoculating
loop, 2mL of 0.45% saline solution (AirLife, Carefusion, CA,
USA) to the equivalent of 1.0 ± 0.3 McFarland (McF) turbidity
standard and thoroughly mixed. 96-well polystyrene plate was
inoculated with 200 µL/well of bacteria suspension. The test
was performed using toner solution (TON004) (Biofilm Control,
Saint Beauzire, France) containing magnetic beads 1% (v/v)
mixed in Brain Heart Infusion medium (BHI, Difco, Detroit, MI,
USA). Next, a set of 10-fold serial dilutions, from 1 × 10−1 to 1
× 10−6 were done in a volume of 200µL BHI/TONmix.
One or more laboratory strains were included in each plate
as standard reference and quality control. A well containing
the BHI/TON mix without microbial cells was used as negative
control in each experiment.
TABLE 1 | Characteristics of clinical isolates used in this study.
Bacterial species Clinical isolates Phenotype Site of isolation
GRAM-NEGATIVE BACTERIA
P. aeruginosa 9 MDR (2) CA-BI (2)
MDR (1) Chronic Ulcer (2)
– Wound (1)
– Urine (1)
– Respiratory (3)
K. pneumoniae 8 KPC (1) CVC (1)
– Blood (2)
– Wound (1)
ESBL (1) CA-UTI (2)
– Respiratory (2)
R. mannitolilytica 8 – Blood (8)
GRAM-POSITIVE BACTERIA
S. aureus 10 MRSA (1) CVC (1)
MRSA (3) Chronic Ulcer (6)
– Skin (2)
– Respiratory (1)
S. epidermidis 8 – Blood (6)
– Wound (2)
Other Gram+ 9 – Blood (2)
VRE (1) Wound (6)
– Urine (1)
Multidrug resistant (MDR), extended spectrum beta-lactamase (ESBL) K. pneumoniae
producing carbapenemases (KPC), methicillin-resistant S. aureus, vancomycin-resistant
enterococci (VRE). Catheter Associated–Urinary Tract Infection (CA-UTI), Central Venous
Catheter (CVC), Catheter Associated Bloodstream Infection (CA-BI).
After 5 h of incubation at 37◦C without shaking (static
culture), wells were covered with a few drops of contrast liquid
(inert opaque oil used) placed for 1min on the block carrying
96 mini-magnets (Block test) and scanned with a specifically
designed plate reader (Pack BIOFILM, Biofilm Control, Saint
Beauzire, France). The adhesion strength of each strain was
expressed as BioFilm Index (BFI), which was calculated by
dedicated software according to Chavant et al. (2007). The values
of BFI were used to measure the biofilm-forming potential (BP),
the latter being a calculation specifically developed for this test, by
using the formula: BP= [1−(BFI sample/average BFI of negative
control)] for each well. The cut-off (BFIc) value was defined
as three standard deviations above the mean of the negative
control wells (BFI= 18.75± 0.32). Values of BP above two times
the cut-off were considered to be significant biofilm formers
(2BFIc ≥ 0.53). Thus, the last dilution above 2BFIc identifies
the ability of the microorganism to form biofilm. Accordingly,
microorganisms were classified into the following categories:
poor biofilm-producer (BP < 2BFIc at 1 × 10−1 McF), weak
(BP > 2BFIc at 1 × 10−1 and/or 1 × 10−2 McF), moderate
(BP > 2BFIc at 1 × 10−3 and/or 1 × 10−4 McF), and high
biofilm producer (BP > 2BFIc at 1 × 10−5 and/or 1 × 10−6
McF). Each microbial culture was analyzed in duplicate and
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experiments were repeated at least three times for each strain to
assess repeatability, accuracy, and precision of the assay. Values
were considered valid when the standard deviation between
duplicates did not exceeded 8%. Replicates showed a complete
categorical accordance within their classification.
Assessment of Bacterial Growth and
Adherence
To further verify the quality of the inoculum and bacterial
growth, the fraction of planktonic and adhering cells was
determined using an inoculum of 105 CFU/mL, from a fresh
overnight culture of bacteria grown on agar plate, and diluted
in 200 µL of BHI medium. Bacterial cells were incubated for 5 h
at 37◦C in a sterile 96-well polystyrene plates without shaking.
The culture supernatants were aspirated to collect the planktonic
cells. Adherent cells were first washed twice in saline solution
and subsequently detached by scraping the bottom of the wells
with a pipet tip and resuspended in 200 µL of sterile distilled
water. The cell suspensions from planktonic and adherent cells
were serially diluted and 5 µL spotted on agar plates. The mean
generation time or doubling time (g) was calculated using the
following equation: log10 Nt = log10 N0 + g log102 where Nt is
the number of cells after 5 h of incubation and N0 is the number
of cells at time zero. The rate of adherence was calculated as
the ratio between adherent cells/planktonic cells doubling times
(adherence index). All assays were performed in triplicate and
repeated in three different experiments.
Evaluation of the Biofilm Formation with
Crystal Violet Assay
Sterile 96-well polystyrene plates were inoculated with 200 µL
of an initial bacterial suspension (105 CFU/ml) in BHI medium
and incubated at 37◦C for 24 and 48 h without shaking. Each
strain was evaluated in triplicate. Medium was removed from the
wells, which were washed three times with 200 µL sterile distilled
water. The plates were air-dried for 45 min and the adherent
cells stained with 200 µL of 0.1% crystal violet solution. After
20min, the dye was removed and the wells washed four times
with 300µL of sterile distilled water to remove excess stain. The
dye incorporated by the cells forming biofilm was dissolved with
200 µL of ethanol/acetone, 80/20% and the absorbance of each
well was measured spectrophotometrically at 570 nm (OD570)
by using the automated PhD
TM
lx System (Bio-Rad Laboratories,
Hercules, CA, USA).
For comparative analysis the OD570 values were used to
classify semi-quantitatively biofilm production for the bacterial
strains according to the method described in Stepanovic et al.
(2000). Briefly, the cut-off OD (ODc) was defined as three
standard deviations above the mean OD of the negative control
and strains were classified as follows: OD< ODc = poor biofilm
producer; ODc< OD< 2× ODc= weak biofilm producer; 2×
ODc < OD < 4 × ODc = moderate biofilm producer; and OD
> 4× ODc= high biofilm producer.
All assays were performed in triplicate, with reference strains
and clinical isolates, and tested on three different experiments.
Statistical Methods
The κ coefficient test was used to determine the agreement
between the results obtained with the cBRT assay and CV.
Strength of agreement was calculated according to Altman
(Altman, 1991): κ = 0.81–1, very good; κ = 0.61–0.80, good;
κ = 0.41–0.60, moderate; κ= 0.21–0.40, fair; κ≤ 0.20, poor. The
results obtained with both procedures were further compared
using the McNemar’s test. P-values of <0.05 were considered
significant.
RESULTS
Measurement of Bacterial Inoculum and
Fraction of Planktonic and Adhering Cells
Since the initial cell concentration may affect biofilm formation
and consequently the reliability of the test, the accuracy
of the initial inoculum for the different microorganisms,
including mucoid or non-mucoid strains, was determined with
a densitometer, and further confirmed by colony-forming unit
(CFU) counts (Welch et al., 2012).
The data reported in Table 2, show that 1 McF unit ranged
from 0.6× 109 ± 2.6× 108 CFU/mL for the R. mannitolilytica to
1.4 × 109 ± 7.2 × 108 CFU/mL for P. aeruginosa, respectively.
The average value of CFU/mL for the planktonic fraction of
different bacterial strains grown to 1 McF corresponded to 1.0
× 109 ± 3.6 × 108, consistent with the range of previously
reported values (Eng et al., 1984; Bhagunde et al., 2010). Hence,
the CFU counts proved that the McF standard is accurate and
reproducible, regardless of the bacterial species or microbial
phenotypes, ensuring that no substantial differences exist in
the initial inoculum when cell concentration is measured by
densitometry.
Subsequently, the growth rate for the 52 clinical isolates and
for the 11 laboratory strains was determined by measuring the
number of planktonic and adhering cells, respectively (Table 3).
This test was performed to evaluate the growth ability of different
bacterial strains in the experimental culture conditions. For this
assessment, the initial inoculum was of 1.0 × 105 CFU/mL. The
results, summarized in Table 3, showed that all the strains had
a similar growth rate. In fact, the lower number of planktonic
cells was found with P. aeruginosa (1.2 × 107 ± 8.8 × 106
TABLE 2 | Corresponding CFU/mL to 1McFarland for the bacteria used to
inoculate the cBRT assay and relative fraction of planktonic and adherent
cells.
Microbial strains Initial inoculum CFU/mL
P. aeruginosa 1.4 × 109 ± 7.2 × 108
K. pneumonia 0.9 × 109 ± 7.9 × 108
R. mannitolilytica 0.6 × 109 ± 2.6 × 108
S. aureus 1.3 × 109 ± 8.4 × 108
S. epidermidis 1.1 × 109 ± 7.1 × 108
Other Gram+ 1.1 × 109 ± 8,7 × 108
Average 1.0 × 109 ± 3.2 × 108
The values represent mean CFU/mL ± SD of two replicates.
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TABLE 3 | Measurement of planktonic and adhering cell fractions for the 52 clinical isolates and the 11 laboratory strains.
Microbial strains Planktonic CFU/mL Planktonic doubling time (min) Adherent CFU/mL Adherent doubling time (min) AI (*)
P. aeruginosa 1.2 × 107 ± 8.8 × 106 43.5 1.5 × 106 ± 1.5 × 106 77.0 1.77
K. pneumoniae 3.2 × 107 ±7.5 × 106 36.1 1.6 × 106 ± 1.3 × 106 75.6 2.09
R. mannitolilytica 2.5 × 107 ± 8.3 × 106 37.7 3.8 × 105 ± 2.9 × 105 155.9 4.13
S. aureus 3.3 × 107 ±1.5 × 107 35.9 2.2 × 106 ± 1.5 × 106 67.6 1.88
S. epidermidis 2.1 × 107 ± 1.2 × 107 38.7 2.0 × 106 ± 1.3 × 106 69.1 1.78
Other Gram+ 2.9 × 107 ± 3.3 × 107 36.6 2.4 × 106 ± 1.5 × 106 65.6 1.79
Average 2.5 × 107 ± 9.7 × 106 37.6 1.7 × 106 ± 7.4 × 105 73.5 1.97
(*) Adherence index (AI) was calculated as the ratio between the doubling time for the adherent fraction vs. the doubling time of the planktonik fraction.
CFU/mL) while the higher number was found with S. aureus
(3.3 × 107 ± 7.5 × 106 CFU/mL) corresponding to a doubling
time of 43.5 and 35.9min., respectively. On the other hand,
the fraction of adhering cells varied from 3.8 × 105 ± 2.9 ×
105 CFU/mL for R. mannitolilytica to 2.5 × 106 ± 1.6 × 106
CFU/mL for the group of the Other Gram+ strains, with a
doubling time of 155.9 and 65.6min., respectively. These results
show that after 5 h of incubation all the strains were able to
adhere to the bottom of the microtiter-plate with no significant
differences between Gram-positive and Gram-negative bacteria.
The analysis of the adherence index (i.e., the ratio between the
doubling time for the adherent fraction vs. the doubling time
of the planktonic fraction), which provides a measurement of
adherent cell production by different strains (Table 3), showed
that the most efficient Gram-negative species was P. aeruginosa,
which produced one adherent cell every 1.77 planktonic cells,
while the most efficient among the Gram-positive bacteria was
S. epidermidis, with an adherence index of 1.78 (Table 3). These
results proved that variations in biofilm production were related
to the specific ability of the different bacterial strains to entrap
magnetic nanoparticle within the newly formed biofilm matrix
and not the result of defective growth capabilities.
Assessment of Biofilm Production in
Gram-Negative and Gram-Positive
Bacteria
Among the 12 P. aeruginosa strains tested, three were
laboratory strains with known ability to form biofilm. These
included Pa47085 (Moderate) (Schaber et al., 2007), Pa14
(Weak) (Rahme et al., 1995), and Pa9027 (High) (Stapleton
et al., 1993), respectively, while the remaining 9 P. aeruginosa
strains were clinical isolates collected from hospitalized patients
(Table 1).
After 5 h of incubation, the reference strain Pa14 immobilized
the magnetic beads only at the highest cell concentration (McF
= 1 × 10−2), thus suggesting low biofilm production ability
(Figure 1A). Likewise, Pa14 was classified as weak biofilm
producer (Table 4A). Conversely, Pa47085 was found to adhere
more readily to the surface of the wells blocking the magnetic
beads at McF = 1 × 10−3, thus identifying this strain as good
biofilm producer. Similarly, Pa9027 was confirmed as a high
biofilm producer at low cell concentration (McF = 1 × 10−6).
These results are consistent with those previously reported for
these laboratory strains (Stapleton et al., 1993; Rahme et al., 1995;
Schaber et al., 2007).
Among the clinical isolates, six strains were found to be
high biofilm producers. In particular, these included all the
three MDR strains, two deriving from patients with catheter-
associated bloodstream infections (Pa6020-IFO, Pa5252-IFO)
and one from a chronic ulcer (Pa5797-IFO), and strains isolated
from a bronchoalveolar lavage of a patient with Cystic Fibrosis
(Pa0629-IFO), from the pleural fluid (Pa5291-IFO) and from
a patient with an infected wound (Pa0118-IFO). Two strains
derived from a chronic ulcer (Pa3019-IFO) and from the
bronchoalveolar lavage from a Cystic Fibrosis patient (Pa0628-
IFO), were classified as moderate biofilm producers. The only
weak biofilm producer was a mucoid strain isolated from a
urinary infection (Pa0115-IFO).
The test was then used to assess the ability of K. pneumonia
to produce biofilm. The results, summarized in Figure 1B
and in Table 4B, showed that the reference strains Kp13883
and Kp700603 were poor and moderate biofilm producer,
respectively, confirming previous reports (Naparstek et al., 2014).
Regarding the clinical strains, Kp0068-IFO (from a urinary
infection), Kp5553-IFO (an ESBL strain from a urinary catheter),
Kp5668-IFO (a KPC strain from a central venous catheter) and
Kp5776-IFO (from pleural fluid) were found to be moderate
biofilm producers. Conversely, the strains isolated from blood
cultures (Kp5656-IFO, Kp5281-IFO, Kp5783-IFO, Kp3040-IFO),
but not deriving from catheter-related bloodstream infections,
showed a mucoid phenotype and were found to be poor
biofilm producer. These data are consistent with previous
reports indicating a higher frequency of biofilm forming strains
among K. pneumoniae isolated from non-fluid physiologic
environments, and may contribute to explain the difficulty at
eradicating these infections once they are established in solid
tissues (Sanchez et al., 2013). From the restricted number of
clinical isolates analyzed emerged a relatively high incidence of
poor biofilm producer strains. Specifically, we observed that only
50% of the K. pneumoniae included in this study were able to
produce biofilm. This value is in agreement with previous in vitro
studies demonstrating that only 40% of K. pneumoniae isolated
from different materials, were able to produce biofilm (Yang and
Zhang, 2008).
The R. mannitolilytica strains herein analyzed were isogenic
clinical isolates from an outbreak occurred in the Oncology ward
in our hospital in 2014. Two reference strains, R. mannitolilytica
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FIGURE 1 | Biofilm formation on 96 well polystyrene plates for the Gram-negative bacteria after 5 h of incubation at 37◦C: (A) P. aeruginosa (Pa), (B) K.
pneumoniae (Kp), and (C) R. mannitolilytica isolated from the IFO hospital. Images were obtained after magnetization of the plates on the Block Test and scanning
with the Plate Reader. The reference laboratory strains are indicated in bold. Negative controls with only BHI medium and magnetic microparticles are circled in red.
LMG 6866 (De Baere et al., 2001), and R. mannitolilytica
BK931 (Marroni et al., 2003) were assessed for comparison,
although their biofilm production ability was not known.
Results summarized in Figure 1C and Table 4C revealed that
the reference strains LMG 6866 and BK931 were weak biofilm
producers. Accordingly, also the 8 R. mannitolilytica strains,
isolated from blood culture, were poor/weak biofilm producers.
The ability to form biofilm was then explored in
different Gram-positive bacteria. As first, different strains
of Staphylococcus aureus were assessed. According to previous
reports (Luppens et al., 2002; Croes et al., 2009; Latimer et al.,
2012) the reference strains Sa6538 and Sa25923, were found
to be strong biofilm producer (Figure 2A, Table 5A). Among
the clinical isolates, five strains were found to be moderate
biofilm producers (Sa3074-IFO, Sa3050-IFO, Sa0186-IFO,
Sa5674-IFO, and Sa5826-IFO) and three strains, isolated from
patients with chronic ulcers, were classified as high biofilm
producers (Sa3146-IFO, Sa3079-IFO, and Sa3065-IFO). Within
the four MRSA strains tested, two were moderate (Sa0186-IFO,
Sa5826-IFO) and two were high biofilm producers, (Sa3146-IFO,
and Sa3065-IFO), respectively. The only two weak biofilm
producer strains were isolated from children with mild atopic
dermatitis (Sa3032-IFO and Sa0073-IFO). None of the strains
analyzed were found to be poor biofilm producer. These results
are in agreement with previous reports describing the ability of
S. aureus to produce biofilm (Otto, 2008; Periasamy et al., 2012).
The assessment of biofilm production by S. epidermidis,
revealed that the reference strain Se12228 (Zhang et al., 2003)
and Se14990 (Stepanovic´ et al., 2003) were weak and moderate
biofilm producers, respectively (Figure 2B, Table 5B). This result
is consistent with the previous data (Stepanovic´ et al., 2003;
Zhang et al., 2003). The analysis of clinical isolates revealed that 5
out of 6 strains derived from blood cultures (Se5287-IFO, Se5669-
IFO, Se5934-IFO, Se5752-IFO, and Se5845-IFO) were weak
biofilm producers. Whereas, one strain isolated from a catheter-
associated bloodstream infection (Se5993-IFO) was found to be a
moderate biofilm producer. The other two S. epidermidis strains,
isolated from wounds were both classified as moderate biofilm
producers.
Other Gram-positive bacteria, recognized as important
nosocomial pathogens, were analyzed. These included
the Staphylococcus haemolyticus, Streptococcus sanguinis,
Streptococcus agalactiae, Enterococcus faecium, and Enterococcus
faecalis. In these experiments the S. aureus strain Sa25923
was used as reference strain. The results indicated that the S.
agalactiae strains (Sag0140-IFO and Sag0093-IFO), both isolated
from infected ulcers, were moderate/high biofilm producers
(Figure 2C, Table 5C). The E. faecium (Efm5304-IFO) was a
weak biofilm producer, whereas the VRE strain (Efm5515-IFO)
was found to be a moderate biofilm producer.
Species-Specific Distribution Analysis of
the Biofilm Production Phenotype
The analysis of the biofilm production according to the
different bacterial species indicates that among the Gram-
negative bacteria, P. aeruginosa showed the most consistent
biofilm producer phenotype. In fact, 6 strains (67%) were high
biofilm producers, 2 (22%) were moderate and 1 (11%) was
a weak biofilm producer, respectively (Figure 3). Conversely,
4 K. pneumoniae isolates, which account for 50% of the
total, were moderate biofilm producers while the remaining
4 strains were found to be poor biofilm producing bacteria.
Interestingly, both the clinical isolates and the laboratory strains
of R. mannitolilytica, had the weakest biofilm production ability.
Among the Gram-positive bacteria, 3 (20%) strains of S. aureus
were high biofilm producers, 5 (50%) were moderate, and 2
were found to be weak biofilm producers (20%). Within the S.
epidermidis group of clinical isolates, 6 strains had a weak biofilm
producing phenotype (75%) whereas the other 2 (25%) strains
were moderate biofilm producers.
Overall, the analysis of the entire bacterial panel, comprising
52 clinical isolates, revealed that more than 44% (23/52) had
a moderate/high biofilm producer phenotype and 85% (44/52)
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TABLE 4 | Plates analysis obtained with the cBRT protocol for (A) P. aeruginosa, (B) K. pneumoniae and (C) R. mannitolilytica.
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1x10−3 0.09 0.03 0.10 0.13 0.05 0.07 0.07 0.10 0.09 0.15 Moderate 0.75
1x10−4 0.00 0.04 0.07 0.01 0.11 0.12 0.02 0.10 0.10 0.04 Moderate 0.53 Cut-off
1x10−5 0.02 0.06 0.06 0.10 0.09 0.12 0.02 0.09 0.10 0.10 High 0.25
1x10−6 0.03 0.10 0.05 0.03 0.09 0.13 0.01 0.09 0.11 0.09 High 0
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Values reported in the table refer to biofilm-forming potential (BP).
were able to produce biofilm. Among the most efficient biofilm
producers, we found 89% of P. aeruginosa, and 80% of S. aureus
strains, respectively (Figure 3).
Categorical Agreement of the cBRT with
Crystal Violet Staining
The biofilm production ability of the different clinical isolates was
further assessed by the CV assay. The average light absorbance
for different biofilm producing bacteria obtained by the CV assay
is shown in Figure 4. The results revealed that the repeatability
of the CV assay was generally good with only minor differences
observed among the replicates.
The results obtained by the CV assay were then compared
with the data gathered by the cBRT. A full categorical
agreement was defined as the percentage of isolates that
were classified in the same category with both methods. A
partial categorical agreement was recorded when the same
classification was obtained by cBRT and the CV OD570 ±
standard deviation (Table 6). Isolates that did not score in the
full or partial categorical agreement were considered as being in
disagreement.
Globally, the full categorical agreement for the Gram-negative
strains was 68% whereas for the Gram-positive bacteria it was
more than 77%, showing an overall agreement in 72.5% of the
samples analyzed. The partial categorical agreement was found
to be more than 95%, corresponding to 3 misclassifications
out of a total of 63 strains analyzed. Importantly, for all
the discordant results, classification differed by only one
category.
In particular, the full and partial categorical agreement
between cBRT and CV assay for P. aeruginosa were of 83%
and 92%, respectively. For K. pneumoniae, two strains were
classified as poor biofilm producer by the cBRT (Kp3040-IFO;
Kp5783-IFO) and as weak biofilm producers by the CV, while
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FIGURE 2 | Biofilm formation on 96 well polystyrene plates for the Gram-positive bacteria after 5 h of incubation at 37◦C. (A) S. aureus (Sa), (B) S.
epidermidis (Se), and (C) different Gram-positive bacteria isolated from the IFO hospital. Images were obtained after magnetization of the plates on the Block Test and
scanning with the Plate Reader. The reference laboratory strains are indicated in bold. Negative controls with only BHI medium and magnetic microparticles are circled
in red.
a moderate biofilm producer strain (Kp0068-IFO) as found
by cBRT, was classified as high biofilm producer by CV. In
these cases the cBRT and CV showed a partial accuracy of
70%. Regarding the R. mannitolilytica strains, a 90% agreement
was found between cBRT and CV, corresponding to only one
misclassification. A complete categorical agreement between
tests was observed with both S. aureus and S. epidermidis,
whereas for the other Gram-positive bacteria the agreement
was 87%, corresponding to only one misclassification
(Ef5515-IFO).
The categorical agreement between cBRT and CV staining
was further analyzed by applying the McNemar’s test in order
to estimate the specific distribution of false positive and false
negative cases. The results indicated that, for the discordant
identifications, a statistically significant difference exists between
tests (P = 0.007). Specifically, the CV overestimated biofilm
production as compared to the cBRT. This result is not surprising
since it could be ascribed to the non-specific staining property of
the CV. Indeed, CV is known to bind surface negatively charged
molecules, which are present on both the bacteria and the biofilm
extracellular matrix (Extremina et al., 2011). This may lead to an
overestimation of the actual biofilm producing ability of different
strains (Pan et al., 2010; Merritt et al., 2011; Skogman et al.,
2012).
The concordance between the cBRT and the CV was
statistically measured by the κ coefficient. The results showed a
good agreement between tests for the weak (κ = 0.71 ± 0.09;
specificity = 94.3%; accuracy = 85.7%), moderate (κ = 0.63
± 0.11; specificity = 84.8%; accuracy = 84.1%), and high (κ
= 0.73 ± 0.10; specificity = 97.9%; accuracy = 90.5%) biofilm
producers, while for the poor biofilm producer cells the strength
of agreement was moderate (κ = 0.42 ± 0.2; specificity = 91.8%;
accuracy = 92.1%). Overall, the strength of agreement between
these methods was good (κ = 0.66 ± 0.07), with the cBRT
showing high levels of specificity and accuracy (specificity =
92.2%; accuracy= 88.1%).
DISCUSSION
Microbial biofilm represents a major virulence factor, accounting
for a most effective microbial invasiveness and persistence in the
environment and in the host. Simple, cost-effective and reliable
tests to assess biofilm formation still represent an unmet need
for clinical microbiology. In fact, current methods to evaluate
biofilm formation are usually time-consuming, costly, and hardly
applicable in the clinical setting.
The aim of the present study was to develop a simple
and reliable in vitro procedure for the determination and
quantification of biofilm-production for future clinical
applications, based on the BioFilm Ring Test R© (BRT)
technology. The concept behind the BRT technology is
attractive in its simplicity since it is based on the measurement
of the ability of bacteria to trap magnetic microparticles within
the biofilm matrix. However, the methodological approaches
proposed in previous studies posed important limitation for
use of BRT for clinical microbiology testing, providing limited
information about the characteristics and “strength” of microbial
biofilm formation by different microorganisms. In particular,
the original protocol proposed by Chavant et al., was based on
repeated measurements, performed at different time points,
to estimate biofilm formation (Chavant et al., 2007), while, in
subsequent studies (Sulaeman et al., 2010; Crémet et al., 2013),
single measurements at 2 and 24 h, respectively, were proposed.
However, in all these cases, fixed bacterial concentration
were used, posing further, important limitations, since, as
clearly demonstrated in our study, the analysis of a single cell
concentration (at a single time point) is not appropriate to
evaluate the strength of biofilm formation. In fact, we found
that at high bacterial concentration the majority of microbial
strains appear capable of trapping the magnetic beads after 5 h
of incubation (and in many cases even after 2 h). However, at
low bacterial concentration only the strong biofilm-producing
strains are able to prevent the aggregation of the magnetic beads.
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TABLE 5 | Plates analysis obtained with the cBRT protocol for (A) S. aureus (B) S. epidermidis and (C) Various Gram-positive.
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Values reported in the table refer to biofilm-forming potential (BP).
Moreover, by extending the incubation time for up to 24 h, as
described in Crémet et al. (2013), all the strains appear capable
to somehow trap the microparticles. All the above limitations
can strongly affect the discriminatory power of the test and the
reliability of the results.
To overcome these limitations we have introduced substantial
modifications to the original protocols. Namely, instead of
using different time points to estimate the strength of biofilm
formation we introduced a single determination. By reducing
the time of incubation to just 5 h we limited the processing
time avoiding repeated measurements. However, in place of
using a single bacterial concentration we used different dilutions,
based on the concept that the fewer concentrations of bacterial
cells that inhibit the aggregation of the microparticles in 5 h,
the stronger is their ability to produce a biofilm. Conversely,
if high bacterial concentrations are not able to prevent the
aggregation of the microparticles they are considered low biofilm
producers.
In addition, to increase the intra-laboratory reproducibility
and the inter-assay control/validation, reference strains with
well-defined biofilm production ability have been introduced.
Further, a standard approach for assay measurement was
adopted to generate the heat chart using the negative control
as cut-off value: BP = [1-(BFI sample/average BFI of negative
control)] and the numeric evaluation obtained by the delta
BioFilm index (BFI) was substituted with a more intuitive and
explicative classification (poor-weak-moderate and high biofilm
producers).
The modifications introduced by the cBRT (short time of
incubation, absence of extensive handling, internal control/s,
standard cut-off calculation and easy interpretation of the
results) represent a step beyond the state-of-art as compared
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FIGURE 3 | Percentage of clinical isolates from each species classified
according to the biofilm production measured by the cBRT.
to the original methods previously proposed, providing a net
improvement in term of standardization of the assay and clarity
and comparability of the readouts.
The ability of the cBRT to assess biofilm production was
compared with the CV assay, which is a widely used method
for biofilm quantification (Christensen et al., 1985; Stepanovic
et al., 2000; Peeters et al., 2008). According to the κ coefficient,
the overall accordance between tests was satisfactory (κ = 0.66
± 0.07) with the cBRT showing a higher specificity (92.3%)
and accuracy (88.1%) as compared to CV. The full categorical
agreement between cBRT and CV was of 72.5%, whereas the
partial categorical agreement exceeded 96%, with only two
samples misclassified out of 63 strains analyzed. Specifically,
the Gram-negative bacteria showed a reduced accordance
between tests when compared with the Gram-positives. The
full categorical agreement was of 68% for the Gram-negatives
and 77% for the Gram-positives, while the partial categorical
agreement was of 93.3 and 96.6%, respectively. This apparent
discrepancy was mainly accounted by the K. pneumoniae strains,
which were found to be the bacterial species with the lower
categorical agreement between tests (40% full and 80% partial).
Indeed, the higher number of discordant results fell within the
group of poor/weak biofilm producers. In fact, all these strains
showed a mucoid phenotype and this may have affected, at
least partially, the sensitivity of the CV test, which is a non-
specific colorimetric assay. Since CV stains both live and dead
bacteria as well as the biofilm matrix, it can provide only an
indirect quantification of biofilm formation, and this may lead
to an overestimation of the results due to non-specific staining,
particularly when testing mucoid strains (Pan et al., 2010; Merritt
et al., 2011; Skogman et al., 2012). Of note, the overproduction of
mucus does not play a significant role in bacterial attachment and
biofilm matrix formation, although it has been shown to exert
protective roles against the host immune response (Stapper et al.,
2004; Leid et al., 2005).
Conversely, the cBRT, which is based on the physical ability
of the microorganisms to generate a biofilm matrix, which
traps magnetic beads (Chavant et al., 2007), provides a direct
measurement of the genuine ability of different bacterial strains
to produce biofilm. Notably, for all the reference strains, the
results gathered by cBRT were in total agreement with the data
previously reported in the literature. In addition, the different
specificity of the two methods was further confirmed by the
McNemar test, which revealed that in those cases in which
cBRT and CV showed a disagreement, the CV significantly
tended (P = 0.007) to overestimate the results. Other important
differences between cBRT and CV are related to the feasibility
for standardization and the time necessary to complete the
assay. With the cBRT plate preparation requires about 30min
plus 5 h of incubation and a few minutes for plate analysis.
Conversely, the CV assay requires 24/48 h of incubation, repeated
washing steps, and laborious staining procedures (Stepanovic
et al., 2000; Djordjevic et al., 2002). The need for extensive
handling procedure to perform the CV assay has been indicated
as a main cause for large intra- and inter-experimental variations,
which lead to often very large standard deviations (Peeters et al.,
2008). A limited reproducibility is also one of themain drawbacks
presented by other conventional techniques, particularly in high
throughput screening (Peeters et al., 2008).
The cBRT assay was tested by assessing different bacterial
species, with distinct biofilm-forming phenotypes, including
both laboratory strains, and clinical isolates. The measurement
of planktonic and adhering cells for all bacterial strains showed
that all were able to adhere to the bottom of the wells after 5 h
of incubation. Nevertheless, the ability to adhere to a surface
does not provide specific information about biofilm production
(Donlan, 2002), although the level of extracellular (i.e., biofilm)
matrix production has an impact on the adhesion ability of
different strains (Vu et al., 2009; Horn et al., 2013; Dertli
et al., 2015). The proportion of extracellular matrix in biofilms
produced by different strains can vary largely according to the
physiological state and nutrient availability, ranging from 50
to 90% of the total organic matter (Vu et al., 2009; Schwartz
et al., 2012). Consequently, the medium composition may
have a strong impact on the ability of a bacterial strain to
form biofilm and this may have important implications for
assay standardization. To explore this issue, we tested cBRT
also using Tryptic Soy Broth (TSB) as growth medium and
we did not observe significant differences with respect to the
BHI. We also assessed simple saline solutions (0.45 and 0.90%,
respectively), but these media did not support an effective
bacterial growth. Thus, the BHI was chosen as the working
medium for assay standardization. The use of this medium
has been further validated by the results gathered with the 11
reference strains. With the exception of the R. mannitolilytica,
all the laboratory strains were well characterized in term of
their biofilm production ability by different methods, in various
conditions and in separate laboratories.
A further issue, dealing with assay standardization, regards
the use specific plates. In fact, cBRT standardization was based
on the use of polystyrene microtiter plates. However, it is
conceivable that different materials might give differing results.
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FIGURE 4 | Quantitative analysis of biofilm formation by CV staining of clinical isolates. P. aeruginosa, K. pneumoniae, R. mannitolilytica, S. aureus, S
epidermidis, and other Gram-positive bacteria (Ss, S. sanguinis; Sh, S. haemolyticus; Sag, S. agalactiae; Efm, E. faecium; Efs, E. faecalis). The isolates were classified
according to their cut-off values (Poor = OD570 < 0.18; Weak = 0.18 < OD570 < 0.37; Moderate = 0.37 < OD570 < 0.74; High = OD570 > 0.74). Error bars
indicate the standard error. Dashed red lines (- - -) indicate the cut-off values at OD570 <0.37 and at OD570 < 0.74.
Similarly, the cut-off values calculated in the present study should
be considered valid exclusively under the standard conditions
tested. It is therefore necessary, in the pursuing of an optimal
standardization of operating procedures, to further extend the
analysis to additional materials and growth media.
From a clinical perspective it is interesting to note that
the strains with multiple drug resistances were all found to
belong to the moderate/high biofilm producer group. Indeed, as
previously shown, MDRs are more frequently associated with
high biofilm production (Kwon et al., 2008; Rao et al., 2008;
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TABLE 6 | Overall results of adherence for the various bacterial species
obtained by the cBRT protocol and CV staining.
Bacterial
Species
cBRT CV staining Categorical
agreement (%)
P W M H P W M H Full Full + Partial
P. aeruginosa 0 2 3 7 0 2 3 7 83 100
K. pneumonia 5 0 5 0 1 4 3 2 40 80
R. mannitolilytica 1 9 0 0 0 10 0 0 80 100
S. aureus 0 2 6 4 0 1 7 4 92 100
S. epidermidis 0 7 3 0 0 7 2 1 80 100
Other G+ 1 3 4 1 0 6 1 2 60 90
Partial categorical agreement: isolates classified by the cBRT in the same category of the
CV OD570 ± standard deviation. P = Poor, W = Weak, M = Moderate, H = High. Full
categorical agreement: isolates identified in the same category by both procedures.
Abidi et al., 2013; Sanchez et al., 2013). The latter appears
to represent a key feature that can promote antimicrobial
resistance by selecting highly resistant strains exposed to
sub-inhibitory antimicrobial concentrations and by providing
favorable conditions for gene transfer (Wang et al., 2010).
Nevertheless, the relationship between biofilm formation and
antibiotic resistance is still a debated issue to researchers. Several
studies have reported that sub-lethal dose of certain antibiotics
induce biofilm formation (Hoffman et al., 2005; Kaplan, 2011;
Mirani and Jamil, 2011) suggesting that biofilm production may
represent a common response to different external stressors
(Kaplan, 2011). Other reports describe an inverse relationship
between biofilm formation and antibiotic resistance. Studies
on Acinetobacter baumannii contribute to generate uncertainty
around this topic since Gurung et al. reported a positive
relationship between biofilm formation and antibiotic resistance
(Gurung et al., 2013), whereas Perez noticed that strains resistant
tomeropenem resulted weak biofilm producers (Perez, 2015) and
Qi et al. observed that the population exhibiting a more robust
biofilm formation likely contained larger proportion of strains
sensitive to several antibiotics (Qi et al., 2016). However, these
reports are generally based on single-species observations and it
is currently unclear whether there is a quantitative correlation
between biofilm formation and antibiotic resistance (Qi et al.,
2016). In any case, biofilm-embedded microbial cells are more
resistant against environmental stress conditions and present
an increased tolerance to antimicrobials (Beloin and Ghigo,
2005; Percival et al., 2015). In vitro and in vivo experiments
demonstrated that within a biofilm matrix, cells show a much
higher MIC (approximately 10–1000 times) than the same
bacterial cells examined in planktonic growth conditions (Høiby
et al., 2011; Hengzhuang et al., 2012). The effective antibiotic
MIC in vivo for eradication of biofilm-embedded microbial cells
might be therefore impossible to reach by the administration of
antibiotics at doses that appear effective against the planktonic
growth fraction, due to the toxicity, and the side effects of the
drugs, including limitations imposed by renal and/or hepatic
functions.
In very preliminary studies aimed at measuring biofilm
production by cBRT and evaluating the effectiveness of
antibiotic treatment based on classic drug resistance profiling
(antibiogram), data revealed that the antibiotic treatment chosen
on the basis of the antibiogram was effective in 3 out of 5 cases
of medical devices-related infections caused by weak biofilm
producer strains. On the contrary, in 2 out of 5 patients,
harboring infections caused by high biofilm producers, the
antibiotic treatment chosen on the basis of the antibiogram
failed, leading to the removal of the devices. Despite the
limited number of cases, these results suggest that a correlation
exist between the “strength” of biofilm production and the
clinical outcome of the therapeutic intervention based on the
antibiogram. Thus, the assessment of the strength of biofilm
formation may help identify high-risk infections and may help
predict the risk of therapeutic failure, thus providing a key
decision-making element in support to an effective therapeutic
management of “difficult infections,” such as those associated
to medical devices (i.e., starting the antibiotic treatment in
the presence of poor/weak biofilm producers or, alternatively,
anticipating the removal of the device in the presence of high
biofilm producers). In fact, these infections often result in
treatment failure and device removal, despite the implementation
of apparently appropriate therapeutic strategies (Costerton et al.,
2003). In this view, other important applications are foreseen in
dentistry, where biofilm is associated with major dental diseases
such as dental caries and periodontal disease. In addition to
clinical applications, this technology may offer a valuable tool in
the food as well as sanitation industry, including water, and air
systems.
Thus, the cBRT represents a promising tool for clinical
microbiology and may lead to future applications including
the possibility for a direct antimicrobial drug profiling of
biofilm-producing bacteria, to support most effective therapeutic
interventions, as well as the screening of new anti-biofilm agents.
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